Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07417982

Patients With Necrotizing Skin and Soft Tissue Infections Managed Within the SURFAST Care Pathway.

Necrotising soft-tissue infections (NSTIs) are rare and life-threatening skin and soft tissue infections requiring urgent combined medical and surgical management in specialist centres. At Assistance Publique-Hôpitaux de Paris, a multidisciplinary reference network called the SURFAST consortium has been established. This network includes experts in the management of NSTIs, such as intensivists, dermatologists, infectious disease physicians, paediatricians, surgeons, and microbiologists. The consortium manages all NSTI cases referred from the greater Paris area, a large region of France with a population exceeding 12 million.

The SURFAST network comprises care pathways enabling the management of adult and paediatric patients with abdomino-perineal, limb, and cervico-facial NSTIs. All patients managed within this care pathway are included in a prospective, multicentre cohort study. This study examines factors associated with mortality at day 90, long-term sequelae, quality of life, and indicators of the quality of care.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Necrotizing Soft-tissue Infections Fasciitis Fasciitis, Necrotizing Musculoskeletal Diseases

Age range

0 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Hôpital Henri Mondor, 1 rue Gustave Eiffel,

Créteil, Île-de-France Region, 94000, France

Location contact

Nicolas DE PROST, PU-PH

CONTACT

[email protected]

+33 1 45 17 86 37

Nicolas de prost, PH PH

PRINCIPAL_INVESTIGATOR

Thomas URBINA, Dr

CONTACT

[email protected]

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • All patients (adults and children, irrespective of age) managed for suspected or surgically confirmed necrotizing soft-tissue infections (NSTI) • Consent to participate in the study

Exclusion criteria

  • Patient or legal representative's refusal to participate in the study

Treatment and study plan

Primary outcomes

  1. mortality

    Time frame: 90 days

    If the patient is still hospitalized, an on-site visit will be conducted; otherwise, the patient or their relative will be contacted by telephone by an investigator or a study coordinator

Secondary outcomes

  1. hospital mortality

    Time frame: at hospital discharge and within 60 days of hospital admission

    vital status measured at hospital discharge

  2. time from hospital admission to first surgical debridement

    Time frame: within the first 72 hours of hospital admission

    time period measured in hours between first hospital admission and first surgical debridement

  3. functional outcome and quality of life

    Time frame: day 90 post-admission

    measured using the Activity of Daily Living (ADL) and the EQ-5D-5L (EuroQol) French version scores

  4. amputation rate

    Time frame: day 90

    toe or limb amputation performed

  5. annual case volume per centre

    Time frame: 123 months

    number of NSTI cases managed per year in each centre participating in the SURFAST network

  6. bacteriological documentation

    Time frame: At the time of blood culture collection or operative tissue sampling

    bacterial documentation of NSTIs obtained from blood cultures or cultures of operative tissue samples.

Study contacts

Contact information is provided by the study sponsor or research team.

Nicolas DE PROST, PU-PH

CONTACT

[email protected]

+33 1 45 17 86 37

thomas URBINA, Dr

CONTACT

[email protected]

Sponsors and collaborators

Lead sponsor

Assistance Publique - Hôpitaux de Paris

Other

Registry information

Official study title

Patients With Necrotizing Skin and Soft Tissue Infections Managed Within the Great Paris Area SURFAST Care Pathway: a Prospective, Multicenter Cohort Study.

Acronym: SURFAST

Important dates

Study start
2026
Primary completion
2036
Study completion
2036
First posted
Feb 18, 2026
Registry last updated
Feb 18, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.